Abpro (ABP) Competitors $0.32 +0.05 (+18.53%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ABP vs. VTVT, RENB, ALGS, ATNM, PDSB, SNTI, DTIL, NRXP, OSTX, and ZIVOShould you be buying Abpro stock or one of its competitors? The main competitors of Abpro include vTv Therapeutics (VTVT), Renovaro (RENB), Aligos Therapeutics (ALGS), Actinium Pharmaceuticals (ATNM), PDS Biotechnology (PDSB), Senti Biosciences (SNTI), Precision BioSciences (DTIL), NRx Pharmaceuticals (NRXP), OS Therapies (OSTX), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry. Abpro vs. Its Competitors vTv Therapeutics Renovaro Aligos Therapeutics Actinium Pharmaceuticals PDS Biotechnology Senti Biosciences Precision BioSciences NRx Pharmaceuticals OS Therapies ZIVO Bioscience vTv Therapeutics (NASDAQ:VTVT) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Which has stronger earnings and valuation, VTVT or ABP? Abpro has lower revenue, but higher earnings than vTv Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiovTv Therapeutics$1.02M48.26-$18.46M-$3.01-5.13Abpro$180K106.52-$7.23MN/AN/A Do insiders & institutionals believe in VTVT or ABP? 17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 4.2% of vTv Therapeutics shares are owned by insiders. Comparatively, 20.8% of Abpro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is VTVT or ABP more profitable? Abpro's return on equity of 0.00% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets vTv TherapeuticsN/A -121.46% -46.75% Abpro N/A N/A -198.95% Do analysts recommend VTVT or ABP? vTv Therapeutics presently has a consensus price target of $35.50, indicating a potential upside of 130.07%. Abpro has a consensus price target of $4.00, indicating a potential upside of 1,168.23%. Given Abpro's higher probable upside, analysts plainly believe Abpro is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to VTVT or ABP? In the previous week, vTv Therapeutics and vTv Therapeutics both had 1 articles in the media. Abpro's average media sentiment score of 1.87 beat vTv Therapeutics' score of 1.28 indicating that Abpro is being referred to more favorably in the news media. Company Overall Sentiment vTv Therapeutics Positive Abpro Very Positive SummaryAbpro beats vTv Therapeutics on 7 of the 10 factors compared between the two stocks. Get Abpro News Delivered to You Automatically Sign up to receive the latest news and ratings for ABP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABP vs. The Competition Export to ExcelMetricAbproMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.17M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E RatioN/A21.1828.1020.05Price / Sales106.52286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book-1.098.378.665.87Net Income-$7.23M-$55.19M$3.25B$258.55M7 Day Performance54.68%5.88%4.22%3.73%1 Month Performance41.43%17.33%10.51%11.75%1 Year PerformanceN/A4.42%34.40%18.03% Abpro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABPAbproN/A$0.32+18.5%$4.00+1,168.2%N/A$16.17M$180K0.0015Positive NewsGap UpHigh Trading VolumeVTVTvTv Therapeutics1.54 of 5 stars$17.03+1.6%$35.50+108.5%-26.6%$53.57M$1.02M-5.669News CoveragePositive NewsRENBRenovaro2.2249 of 5 stars$0.31+0.1%N/A-75.3%$53.01MN/A-0.4020ALGSAligos Therapeutics4.3029 of 5 stars$9.12+5.6%$70.00+667.5%-32.4%$52.83M$3.27M-0.5290News CoveragePositive NewsATNMActinium Pharmaceuticals2.4484 of 5 stars$1.82+7.7%$4.00+119.8%N/A$52.72MN/A-1.3130PDSBPDS Biotechnology1.2528 of 5 stars$1.15flat$9.00+682.6%-70.1%$52.57MN/A-1.2220SNTISenti Biosciences2.2678 of 5 stars$1.99+0.5%$8.50+327.1%-16.8%$51.64M$2.56M-0.184DTILPrecision BioSciences4.0884 of 5 stars$4.86+4.5%$47.00+867.1%-49.4%$51.56M$51.14M-2.42200Upcoming EarningsNRXPNRx Pharmaceuticals2.5264 of 5 stars$2.99+0.3%$28.50+853.2%+28.2%$51.52MN/A-1.492OSTXOS Therapies2.0633 of 5 stars$1.82+7.7%$18.00+889.0%N/A$51.14MN/A-2.12N/AGap UpZIVOZIVO BioscienceN/A$13.25flatN/A+30.2%$50.58M$15.85K-2.7210 Related Companies and Tools Related Companies VTVT Alternatives RENB Alternatives ALGS Alternatives ATNM Alternatives PDSB Alternatives SNTI Alternatives DTIL Alternatives NRXP Alternatives OSTX Alternatives ZIVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABP) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abpro Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abpro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.